Assessment of patients response and expression levels of CITED2 and HIF2a genes on adding pioglitazone to imatinib therapy.
Eligible denovo CML patients will be treated by combination drug therapy of imatinib 400 mg plus pioglitazone (15 - 30mg).They will be on follow up for their complete blood count (CBC), chemistry profile and random blood sugar every 2 weeks. After 3, 6 and 12 months of treatment the patients response will be evaluated and compared with the obtained responses of a historical control group. Assessment of the hypoxia induced factor 2 alpha (HIF2a) gene and CBP/p300-interacting transactivator with glutamic acid (E) and aspartic acid (D)-rich tail 2 (CITED2) gene expression levels before and after 6 months of treatment will be additionally evaluated.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
90
pioglitazone (7.5-30 mg) once daily plus imatinib 400 mg 6 months
Faculty of Medicine
Al Mansurah, Dakahlia Governorate, Egypt
Rate of major molecular response(MMR) at 12 months
Percentage of patients obtaining MMR at 12 months
Time frame: 1 year
Impact of treatment on the expression levels of stemness genes
Follow up the expression of CITED2 and HIF2a genes pattern
Time frame: 6 months
Impact of treatment on the rate of transformation
Progression into accelerated or blastic phases
Time frame: 1 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.